Prostate Cancer Drug Roars Ahead

The prostate cancer market is roaring ahead thanks to Johnson & Johnson's (NYSE: JNJ  ) $970 million purchase of Cougar Biotechnology. Abiraterone, the drug that Johnson & Johnson got in the deal, gained Food and Drug Administration approval yesterday.

Approval of the drug, which will be marketed as Zytiga, came considerably earlier than its PDUFA date of June 20. Ironically -- or perhaps a sign the agency loves prostate cancer drugs -- sanofi-aventis' Jevtana, which Zytiga will compete with, had a similar experience. Both drugs are approved for prostate cancer patients that have failed a round of sanofi's Taxotere.

Dendreon's (Nasdaq: DNDN  ) Provenge is safe for now. Provenge is approved as a first-line treatment for metastatic castration-resistant prostate cancer before chemotherapy is used. It's possible that doctors might prescribe Zytiga off-label for patients earlier in their disease progression, but they may run into resistance from insurance companies that aren't willing to pay the high price. Hospira (NYSE: HSP  ) launched a generic version of Taxotere last month, which insurers may require patients try before moving onto the more expensive stuff.

Johnson & Johnson's, Dendreon's, and Sanofi's biggest problem might not be competing among themselves, but the plethora of prostate cancer drugs in development. Medivation's (Nasdaq: MDVN  ) MDV3100 and OGX-011 from OncoGenex Pharmaceuticals (Nasdaq: OGXI  ) and Teva Pharmaceuticals (Nasdaq: TEVA  ) could both make it to market if their phase 3 trials are successful. Exelixis' (Nasdaq: EXEL  ) cabozantinib is farther behind, but the phase 2 data in prostate cancer patients looked good.

Roaring ahead tends to be good for patients, but not so much for those already on the market.

Johnson & Johnson is a Motley Fool Inside Value selection. Exelixis is a Motley Fool Rule Breakers recommendation. Teva Pharmaceutical Industries is a Motley Fool Global Gains choice. Johnson & Johnson is a Motley Fool Income Investor selection. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Exelixis, Johnson & Johnson, and Teva Pharmaceutical Industries. Alpha Newsletter Account LLC owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1485456, ~/Articles/ArticleHandler.aspx, 11/21/2014 6:03:33 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement